Изучение прогностического значения накопления онкопротеина Р53 у больных злокачественными лимфомами
Диссертация
В опухолях человека наиболее часто (по сравнению с другими генами) выявляются мутации гена р53. По данным литературы, не менее 50% опухолей человека экспрессируют мутированную форму гена р53. Обнаруженный вначале как опухолевый антигенсвя-занный белок в трансформированных вирусом SV40, р53 в настоящее время является одним из центральных факторов, присутствующих в большинстве опухолей человека… Читать ещё >
Содержание
- Глава 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Прогностические факторы при злокачественных 11 лимфомах
- 1. 2. Апоптоз — программированная клеточная гибель. 18 Роль апоптоза в канцерогенезе
- 1. 3. Клеточные онкогены — индукторы канцерогенеза
- 1. 4. Протоонкоген р53 — важный регулятор апоптоза. 22 Структура, механизмы активации
- 1. 5. Функции, структура и механизм действия 25 онкопротеина Р
- 1. 6. Протеины семейства Р
- 1. 7. Накопление протеина Р53 при лимфопролиферативных 28 заболеваниях
- 1. 8. Особенности накопления протеина BCL-2 в тканях
- 1. 9. Накопление протеина BCL-2 при лимфопролифера- 32 тивных заболеваниях
- 1. 10. Накопление протеина Р53 и лекарственная 33 устойчивость
- 1. 11. Целенаправленная индукция апоптоза — стратегия 34 разработки новых противоопухолевых лекарств
- Глава 2. МАТЕРИАЛЫ И МЕТОДЫ ИССЛЕДОВАНИЙ
- 2. 1. Общая клиническая характеристика больных
- 2. 2. Методы клинического обследования больных НЛ
- 2. 3. Иммуногистохимический метод
- 2. 4. Методы статистической обработки результатов
- Глава 3. РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ И ОБСУЖДЕНИЯ
- 3. 1. Характер накопления протеина Р 53 48 при различных видах злокачественных лимфом
- 3. 2. Особенности продукции протеина Р53 при 49 агрессивнных НЛ
- 3. 3. Особенности продукции Р53 при индолентных НЛ
- 3. 4. Особенности продукции протеина Р53 при болезни 58 Ходжкина
Список литературы
- Бармина Н.М., Двойрина В. В. Статистика злокачественных лимфом в 1990 году // Современные методы диагностики и лечения злокачественных лимфом. — СПб. -1992. -С. 13−14.
- Белоусова А. К. Загадки гена опухолевого супрессора р53 // Эксперим. онкол. -1996.- Т. 18, № 4.— С. 197−208.
- БеттичерД.А. Новые мишени противоопухолевой терапии// Материалы конференции «Современные тенденции развития лекарственной терапии опухолей». М., 1997.- С. 10−16.
- Бутенко З.А. Онкогены регуляторы апоптоза в механизмах лимфо- и канцерогенеза // Эксперим. онкол.-1995.-Т. 17,№ 3.-С.165−171.
- Бутенко З.А. Программированная клеточная гибель при злокачественных лимфомах // Доп.нац.акад.наук.Укр.-1999.-№ 1.-С.185−187.
- Владимирская Е.Б., Масчан А. А., Румянцев А. Г. Апоптоз и его роль в развитии опухолевого роста // Гематол. трансфузиол. -1997.—Т.42, № 1.— С. 4−9.
- Воробьёв А.И., Бриллиант М. Д. Руководство по гематологии: В 2-х т. / Под ред. А. И. Воробьёва. 2-е изд., перераб. и доп. — М: Медицина, 1985.
- Диагностика и лечение злокачественных лимфом. Под ред. Новика А. А. // Информационные материалы кафедры гематологии и клинической иммунологии Военно-медицинской академии к конференции. СП6.-1997.- С.64−81.
- Животовский Б.Д., Хансон К. П. Роль активации генома в программируемой клеточной гибели // Биополимеры и клетка. -1985. Т. 1, № 4. — С. 199 — 203.
- Журавлёв B.C., Вашурина Е. А., Орлова А. Д. и др. Исследование сывороточных иммуноглобулинов у больных злокачественными лимфомами // Пробл. гематологии и переливания крови.1982.- Т.27, № 3. С. 22−24
- Иммунологические аспекты лимфопролиферативных заболеваний II Под ред. В. П. Лозового, Г. З. Ширинского. -Новосибирск: Наука, -1987. -151 с.
- Канаев С.В., Малинин А. П., Кордыш Ф. С. Результаты терапии лимфогранулематоза в лечебных учреждениях Санкт-Петербурга II «Современные методы диагностики и лечения злокачественных лимфом» Тезисы симпозиума. -Псков. -1992. -С. 14−15.
- Капитаненко A.M., Дочкин И. И. Клинический анализ лабораторных исследований / Под ред. Е. В. Гембицкого: 2-е изд., перераб. и доп. — М.: Военное издательство, -1988. -270 с.
- Лихтенштейн А.В., Шапот B.C. Опухолевый рост: ткани, клетки, молекулы II Пат. физиол.-—1997.--№ 3.—С. 35−48.
- Лушников Е.Ф., Загребин В. М. Апоптоз клеток: морфология, биологическая роль, механизмы развития //Архив патологии.-1987. -Т. 49, N92. -С. -84−9.
- Мазуров В.И., Антонов В. Б., Новик А. А. и соавт. Клинико-морфологическая характеристика неходжкинских злокачественных лимфом // Врачебное дело. -1992. № 3. — С. 38 — 40.
- Молекулярная клиническая диагностика. Методы. Под редакцией Харрингтона С., Макги Дж., пер. с англ.- М: Мир.-1999.-С.20−64
- Новик А.А. Классификация злокачественных лимфом. СПб: ЭЛБИ.- 2000.-С.126.
- Новик А.А., Белохвостое А. С. Молекулярно-генетический подход к диагностике злокачественных лимфом // Вопр. онкологии -1998.-Т.44, № 3, -С. 274−279.
- Математико-статистические методы в клинической практике / Учебное пособие. Под редакцией Кувакина В. И. СПб: ВМедА.-1993.-С. 62−95.
- Пальцев М.А., Коган Е. А., Тунцова О. И. Иммуногистохимия биомолекулярных маркеров раннего рака щитовидной железы //Арх. пат. -1997.—Вып.6.—С. 18−23.
- Погорелов В.М., Козинец Г. И. Морфология апоптоза при нормальном и патологическом гемопоезе // Гематол. транфузиол. -1995. -Т. 40, № 5. -С.17 -25.
- Программированная клеточная гибель. /Под ред. Новикова
- B.C.- СПб: Наука.-1996.-С.157.
- Робинсон М.В., Труфакин В. А. Апоптоз клеток иммунной системы // Успехи соврем, биологии. -1991 .-Т.111 ,№ 2,1. C.246- 259.
- Ройт А. Основы иммунологии: Пер. с англ. М.: Мир, -1991. -С.165.
- Уманский С.Р. Апоптоз молекулярные и клеточные механизмы // Молекулярная биология.-1996.-Том.30,№ 5,-С.487−502.
- Фильченков А.А. Современные представления о роли апоптоза в опухолевом росте и его значении для противоопухолевой терапии. // Экспер. онкол.—1998.—Т.20., № 5.—С.259−270.
- Фильченков А.А., Стойка Р. С. Апоптоз (физиологическая гибель клетки) //Семинары по гематологии.—1995.--№ 2.— С. 1−24.
- Флетчер Р., Флетчер С., Вагнер Э., Клиническая эпидемиология. Основы доказательной медицины М: Медиа Сфера. -1998.-С. 141−70.
- Я рилин А. А. Апоптоз и его место в иммунных процессах // Иммунология.—1996.~№ 6.—С. 10−23.
- Andersen T.I., Holm R., Nesland J.M. et al. Prognostic significance of TP53 alteration in breast carcinoma // Brit. J. Cancer.—1993.— Vol. 68.—P.540−549.
- Ansell S., Kurtin P., Stenson M. et al. Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index // leuk. Lymphoma. -1999. Vol. 34, № 5 — 6. — P. 529 — 537.
- Armstrong A., Alexander F.E., Cartwright R. et al. Epstein-Barr virus and Hodgkin’s disease: further evidence for the three disease hypothesis // Leukemia. 1998. — Vol. 12. — P. 1272 — 6.
- Bellamy C.O., Malcomson D.G. Cell death in health and disease: the biology and regulation of apoptosis // Semin. Cancer Biology.— 1995.—Vol. 6.—P.3−16.
- Banadonna G., Saccani Jotti G. Prognostic factors and response to treatment in non-Hodgkin's lymphomas // Anticancer Res. -1987. -Vol. 7, № 4. P. 685−694.
- Berchuk A. Biomarcers in the ovary // J. Cell. Biochem.—1995.— Vol.23.—P.223−226.
- Bergh J. Importance of p53 in the diagnostic and treatment of cancer. // 23 ESMO congress. -1998. -P.604−608.
- Blay J., Gomez F., Sebban C. et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group II Blood. -1998. -Vol. 92, № 10. P.3562−3568.
- Bloomfield C., Arthur D., Frizzera G. et al. Non-random chromosomeabnormalities in lymphoma // Cancer Res.-1983. -Vol.43. -P.2975.
- Bloomfield C., Me Kenna R., Brunning R. Significance of hematological parameters in non-Hodgkin's malignant lymphomas // Brit. J. Haemat. -1976. -Vol. 32. -P. 41- 46.
- Bocchia M., Xu Q., Wesley U. et al. Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells // Leuk. Res. -1997. Vol. 21, N5.1. P. 439−447.
- Bomer M.M., Brousset P. et al. Expression of apoptosis regulatory proteins of the bcl-2 family and p53 in primary resected non-small lung cancer// Brit. J. Cancer.—1999.—Vol.79.—P.952−958.
- Boyle M., Vasak E., Tschuchnigg M et al. Subtypes of Epstein-Barr virus (EBV) in Hodgkin’s disease: association between B-type EBV and immunocompromise // Blood. -1993. Vol. 81, № 2. — P.468
- Bratstrom D., Bergqvist M., Lamberg K. et al. Complete sequence of p53 gene in 20 patients with lung cancer: comparison wit chemo-sensitivity and immunohistochemistry // Med. Oncolio 1998. -Vol.15.-P. 255−261.
- Breast Cancer. Diagnosis, Therapy and Prognosis. 3rd edition. DACO. -1996. -P.4.
- Brink A., Oudejans J., van-den-Brule-AJ et. al. Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin’s disease: involvement of apoptosis resistance? // Mod. Pathol. 1998. — Vol. 11, N4. — P 376−383.
- Calabretta В., Skorski Т., Ratajezak M. et al. Antisense strategies in the treatment of leukemias // Semin.Oncol. -1996. -Vol.23. -P.78−87.
- Carbone P., Kaplan H., Musshoff K. et. al. Report of the Committee on Hodgkin’s disease staging classification // Career Res. -1971. -Vol. 31.-P. 1860−1861.
- Coller В., Chabner В., Gralnick H. Frequencies and patterns of bone marrow involvement in non-Hodgkin's lymphomas: observations on the value of bilateral biopsies II Am. J. Hematol. -1977. Vol. 3. -P. 105−119.
- Colombol M., Symmans F., Gil S. et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory human prostate cancer//Am. J. Pathol. -1993. -Vol.143. -P.390−400.
- Concato J., Feinstein A. et al. The risk of determining risk with multivariable models //Ann. Intern. Med.-1993. -Vol.118.1. P. 201−210.
- Conill C., Verger E., Salamero M. Performance status assessment in cancer patients// Cancer. -1990. -Vol.65. -P. 1864−1866.
- Conlan M., Armitage J. et al. Clinical significance of hematological parameters in non-Hodgkin's lymphoma at diagnosis // Cancer. -1991.-Vol.67.-P. 1389−95.
- Cooper K., Haffajee Z. bcl-2 and p53 protein expression in follicular lymphoma II J. Pathol. -1997. Vol. 182, N3. — P. 307−10.
- Korsmeyer S. J. BCL-2: a repressor of lymphocyte Death // Immunology.—1992.—Vol. 13.—P. 285−288.
- Deckert-Schluter M., Rang A., Wiestler 0. Apoptosis and apoptosis-related gene products in primary non-Hodgkin's lymphoma of the central nervous system II Acta. Neuropathol. Berl. 1998. — Vol. 96, N2.-P. 157−162.
- Delage R., Roy J., Jacques L. et. al. Multiple bcl-2/lg gene rearrangements in persistent polyclonal B-cell lymphocytosis // Br. J. Hematol. -1997. Vol. 97, N3. — P. 589−595.
- Delia D., Aiello A, Soligo D. et al. bcl-2 protooncogene expression in normal and neoplastic human myeloid cells // Blood. -1992. -Vol.79. -P.1291−1298.
- Deter S., Saccani G., Dowsett M. «Quickscore» method for immunohistochemical semiquantitation validation for estrogen receptor in breast carcinomas // J. Clin. Pathol. -1995. -Vol.48. -P.876−878.
- Doussis I., Pezzella F. et al. An immunocytochemical study of p53 and bcl-2 protein expression in Hodgkin’s disease //Am. J. Clin. Pathol. -1993. -Vol.99. -P.663−667.
- Dunphy С., Lattuada С. Follicular center cell lymphoma with an extremely high content of T cells: case report with useful diagnostic techniques // Arch. Pathol. Lab. Med. -1998. Vol. 122, N10.1. P. 936−938.
- DziecioL J., MaLdyk J., Zimnoch L. et al. Expression of MPM2, p53 and Bcl2 proteins in Hodgkin’s disease // Folia histochemica et cytobiologica. -1999. -Vol.37.№ 2. P.147−148.
- Engert A., Pohl C., Diehl V. Experimental therapy in Hodgkin’s disease II Ann. Oncol. -1992 (3 suppl 4). -P.97−100.
- Feller A., Griesser H. DNA gene rearrangement studies in Hodgkin’s disease and related lymphomas. Recent results // Cancer Res.-1989. -Vol.117. -P.27−34.
- Finger L., Harvey R., Moore R. et al. A common mechanism of chromosomal translocation in T- and B-cell neoplasia II Science. -1986. -Vol.234. -P.982−985.
- Fonatsch C., Diehl V., Schadt M. et al. Cytogenetic investigations in Hodgkin’s disease: Involvement of specific chromosomes in marker formation //Cancer. Genet. Cytogenet. -1986. -Vol.20. -P.39−52.
- Foon K. Laboratory and clinical applications of monoclonal antibodies for leukemia and non-Hodgkin's lymphomas // Curr. Probl. Cancer. -1989. -Vol.13. -P.57−128.
- Fukuhara S., Rowley J., Variakojis D. et al. Chromosome abnormalities in poorly differentiated lymphocytic lymphoma // Cancer Res. -1979. -Vol.39. -P.3119−3128.
- Gaffey M., Weiss L. Viral oncogenesis: Epstein-Barr virus // Am. J. Otolaryngol. 1990. — Vol. 11, № 6. — P. 375 — 381.
- Gaidano G., Dalla-Favera R. Protooncogenes and tumor suppressor genes // Neoplastic Hematopathology. Baltimore: Williams and Wilkins. -1992. P.245−261.
- Gaidano G., Pastore C., Capello D. et. al. Molecular pathways in low grade B-cell lymphoma II Leuk. Lymphoma. -1997. Vol. 26, Suppl 1.-P. 107−113.
- Gascoyne R., Adomat S., Krajewski S. et. al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma // Blood. -1997. Vol. 90, N1. -P. 244−251.
- Gaulard P., d’Agay M., Peuchmaur M. et al. Expression of the bcl-2 gene product in follicular lymphoma II Am. Л Pathol. 1992. -Vol.140. -P. 1089−1095.
- Gause A., Jung W., Schmits R. et al. Soluble CD8, CD25, and CD30 antigen as prognostic markers in patients with untreated Hodgkin’s lymphoma //Ann. Oncol. -1992. -Vol.3. Suppl 4. P. -49−52.
- Geelen F., Vermeer M., Meijer C. et. al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma II J. Clin. Oncol. 1998. -Vol. 16, N6. — P. 2080−2085.
- Ghia P., Boussiotis A., Schultze J. et. al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival // Blood. -1998. Vol. 91, N1.1. P. 244.
- Gisbertz I., Schouten H., Bot F. et al. Proliferation and apoptosis in primary gastric B-cell non-Hodgkin's lymphoma // Histopathology. -1997. Vol. 30, N2. — P. 152−159.
- Griesser H., Tkachuk D. et al. Gene rearrangements and translocations in lymphoproliferative diseases II Blood. 1989. -Vol.73.-P. -1402−15.
- Hall A., Maclean F., Reid M. et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia // Leukemia. -1995. -Vol.9, N3. -P.530.
- Haluska F., Finger L., Kagan J. et al. Molecular genetics of chromosomal translocations in B- and T-lymphoid malignancies. Molecular Genetics in Cancer Diagnosis // Edited by J Cossman. New York, Elsevier.- 1990.-P.143- 162.
- Hanada M., Delia D., Aiello A. et al. bcl-2 gene hypometilation and high level expression in B-cell chronic lymphocytic leukemia // Blood. -1993. -Vol. 82. -P. 1820−1828.
- Harris N., Jaffe S., Stein H. et al. A Revised European-American Classification of Lymphoid Neoplasm: A Proposal From the International Lymphoma Study Group II Blood. -1994. Vol. 84, № 5.-P. 1361 -1392.
- Hayward R., Leonard R., Prescott R. et al. A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma // Br. J. Cancer. -1991. -Vol. 63, № 6.1. P. 945−52.
- He H., Lam M., McCormick T. et al. Maintenance of calcium homeostasis in the endoplasmic reticulum by Bcl-2 // J. Cell. Biol. -1997. Vol. 138, N6. — P. 1219−1228.
- Heim S., Mitelman F. Cancer Cytogenetics //Alan R. Liss Inc. New York. -1987.-P.201−225.
- Henriksen R. Expression and prognostic significance of Bcl-2 //Br. J. Cancer. -1995. -Vol.72. -P.1324−1329.
- Herbst H., Raff Т., Stein H. Phenotypic modulation of Hodgkin and Reed-Sternberg cells by Epstein-Barr virus // J. Pathol. 1996. -Vol.179.-P.54−59.
- Hermans J., Krol A.D., van-Groningen K. et al. International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades // Blood. -1995. Vol. 86. — № 4. P. 1460.
- Hermine 0., Haloun C., Lepage E. et al. Bcl-2 protein expression in agresssive non-Hodgkin's lymphoma. A new adverse prognostic factor? A GELA Study. Fifth International Conference on Malignant Lymphoma, Lugano. -1993. Abstr.16.
- Hill M., MacLennan K. et al. Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma. A British National Lymphoma Investigation study// Blood. -1996. -V0I.-88. P. 1046.
- Hockenberry D., Oltvai Z., Yin X. et al. bcl-2 functions in an antioxidant pathway to prevent apoptosis // Cell. -1993. -Vol.75. -P.241−251.
- Hoffbrand A. Postgraduate Hematology // Third edition. -1992.
- Hoffman R., Benz E.J., Sanford J. et al. Hematology Basic Principles and Practice // Churchill Livingstone, London. 2000. -P.1294.
- Hsu В., Marin M. Expression of bcl-2 gene confers multidrug resistance to chemotherapy-induced cell death // Cancer Bull. -1994. -Vol.46, N2. -P. 125- 129.
- Inagaki H., Banno S., Wakita A. et al. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma // Mod. Pathol. 1999. -Vol. 12, № 5.-P. 546−552.
- Kanavaros P., Stefanaki K., Vlachonikolis J. et al. Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin’s lymphomas // Histology and Histopathology. 2000. -Vol.15, № 2. -P.445−453.
- Kaneko Y., Rowley J., Variakojis D. et al. Prognostic implications of karyotype and morphology in patients with non-Hodgkin's lymphoma // Int. J. Cancer. -1983. -Vol.32. -P.683- 692.
- Kerr J., Wyllie A., Currie A. Apoptosis: a basic biological phenomenon with wide-ranging implication in tissue kinetics II Br. J. Cancer. -1972. -Vol.26, N4. -P.239−257.
- Kerr J., Winterford C., Harmon B. Apoptosis: its significance in cancer therapy II Cancer. -1994. -Vol.73. -P.2013- 2026.
- Koduru P., Filippa D., Richardson M., et al. Cytogenetic and histologic correlations in malignant lymphoma // Blood. -1987. -Vol.69.-P.97−102.
- Korsmeyer S., bcl-2 initiates a new category of oncogenes: regulators of cell death // Blood. -1992. -Vol.80. -P.879- 886.
- Kramer M., Hermans J et al. Clinical significance of bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study // J. Clin. Oncol. -1996. -Vol.14. P. 2131−2138.
- Kramer M., Hermans J., Wijburg E. et al. Clinical relevance of BCL2, BCL6, and МУС rearrangements in diffuse large B-cell lymphoma II Blood. -1998. -Vol.92,№ 9. -P.3152- 3162.
- Kusenda J. Bcl-2 family proteins and leukemia. Minireview II Neoplasma. -1998. Vol. 45, N3. — P. 117−122.
- Lee M., Chang K., Cabanillas F. et al. Detection of minimal residual carrying the t (14−18) by DMA sequence amplification // Science.-1987.-Vol.237.- P.-175−178.
- Lindvall L., Lantz M., Gullberg U. et al. Modulation of the constitutive gene expression of the 55 kD tumor necrosis factor receptor inhaematopoietic cells// Biochem. Biophys. Res. Commun. -1990. -Vol. 172, № 2. -P. 557−563.
- Lo Coco F., Gaidano G.L., Louie D.C. et al. p53 mutations are associated with histologic transformation of follicular lymphoma // Blood. -1993. -Vol.82. P. 2289- 2295.
- Loeffler M., Mauch P., MacLennan K. et al. Review on prognostic factors // Ann. Oncol. -1992. -Vol.3, suppl 4. P. 63- 66.
- Lopez Guillermo A., Montserrat E., et al. A study of prognostic factors and assessment of five recently proposed predictive systems II Leukemia and Lymphoma. -1993. -Vol.10. — P.101−109.
- Lopez-Guillermo A., Cabanillas F., McLaughlin P. et. al. The clinical significance of molecular response in indolent follicular lymphomas // Blood. -1998. Vol. 91, N8. — P. 2955- 2960.
- Lorenzen J., Hansmann M. et al. Expression of the bcl-2 oncogene product and chromosomal translocation t (14- 18) in Hodgkin’s disease// Hum. Pathol. -1992. -Vol.23. -P. 1205−1209.
- Lu Q., Elia G., Lucas S. et al. bcl-2 protooncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma II Cancer. -1993. -Vol.53. P.29−35.
- Lu Q.L., Poulsom R., Wong L. etal. BCL-2 expression in adult and embryonic non-haematopoietic tissues // J. Pathol.- 1993.-Vol.169.-P.431- 437.
- Mac Lennan I.C.M. Germinal centers//Ann. Rev. Immunol. -1994. -Vol.12.-P.117−139.
- Marin M., Hsu В., Meyn R. etal. Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for lymphomagenesis // Oncogene.-1994.-Vol.9.- P.3107- 3112.
- Marin M., Hsu В., Stephens L. et al. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo II Exp. Cell. Res.-1995. -Vol.217. -P.240−247.
- Martinka M., Comeau Т., Foyle A. et. al. Prognostic significance of t (14−18) and bcl-2 gene expression in follicular small cleaved cell lymphoma and diffuse large cell lymphoma II Clin. Invest. Med. -1997. Vol. 20, N6. — P. 364−370.
- Matolcsy A., Warnke R., Knowles D. Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma //Ann-Oncol. 1997. — Vol. 8, Suppl 2. — P. 119−122.
- McClelland R.A., Wilson D., Leake R. et al., A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification II Eur.J.Cancer. -1991. -Vol.27. -P.711- 715.
- McDonnel N. Marin V., Hsu V. et al. Bcl-2 oncogene: apoptosis and neoplasia // Radiation Res.-1993. -Vol.136. -P.307- 312.
- McDonnell Т., Deane N., Piatt F. et al. bcl-2 immunoglobulin transgenic mice demonstrate extended В cell survival and follicular lymphoproliferation II Cell. -1989. -Vol. 57. -P. 79−88.
- McDonnell Т., Korsmeyer S. Progression from lymphoid hyperplasia to high grade malignant lymphoma in mice transgenic for the t (14−18) II Nature.- 1991.-Vol.349.-P. 254- 256.
- Meijerink J. t (14−18), a journey to eternity II Leukemia. -1997. Vol. 11, N12.-P. 2175−2187.
- Miettinen M., Sarlomo-Rikala M., Kovatich A. Cell-type- and tumour-type-related patterns of bcl-2 reactivity in mesenchymal cells and soft tissue tumors II Virchows. Arch. -1998. Vol. 433, N3.1. P. 255- 260.
- Milner A., Grand R., Vaughan A. et. al. Differential affects of BCL-2 on survival and proliferation of human B-lymphoma cells following gamma-irradiation II Oncogene. -1997. Vol. 15, N15. — P. 1815−22.
- Monni 0., Franssila K., Joensuu H. et al. BCL2 overexpression in diffuse large B-cell lymphoma // Leuk. Lymph. -1999. -Vol. 34. -N1−2. -P.45−52.
- Montserrat E. Chronic lymphoproliferative disorders // Curr. Opin. Oncol. -1997. Vol. 9, N1. — P. 34−41.
- Morrison V., Frizzera G., Arthur D.C. et al. Prognostic factors for therapeutic outcome of diffuse small non-cleaved cell lymphoma in adults // Am. J. Hematol. -1994. Vol. 46, № 4. — P. 295 — 303.
- Nakimine H., Bagin R.G., Vase J.M. et al. Prognostic significance of clinical and pathologic features in diffuse large B-cell lymphoma // Cancer. -1993. -Vol. 71. -P. 3130−3136.
- Navone R., Pich A., Fiammotto M. et al. Bone marrow Histopatho-logy and prognosis in malignant lymphomas // Tumor. 1992. — Vol. 78, № 3. — P. 176−180.
- Negrin R., Blume K. The use of polymerase chain reaction for the detection of minimal residual malignant disease // Blood. -1991. -Vol.78. -P.255- 258.
- Ngan В., Weiss L., Warnke R. et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t (14−18) translocation II New Engf. J. Med.-1988. -Vol.318. -P.1638−1644.
- Nomdedeu J., Baiget M., Gaidano G. et. al. p53 mutation in a case of blastic transformation of follicular lymphoma with double bcl-2 rearrangement (MBR and VCR) // Leuk-Lymphoma. 1998. — Vol. 29, N5−6. — P. 595−605.
- Obrams G., O’Conor G. The emerging epidemic of non-Hodgkin's Lymphoma: current knowledge regarding etiological factors. Timetrends and pathological classification: a summary // Cancer Res. -1992. Vol. 52, № 19. — P.5570.
- Ohshima K., Kikuchi M. et al. Bcl-2 gene and prognosis of B-cell lymphoma//Leuk. Lymphoma. -1991. -Vol.5. -P. 305.
- Ott M., Muller-Hermelink H. et al. Chromosomal translocation detected by bcl-1 and bcl-2 rearrangement in low-grade B-celi lymphomas in a European population // Hystopatology. -1991. -Vol.19.-P. -163−167.
- Palestro G., Ponti R., Chiusa L. et. al. Cell proliferation, bcl-2, c-myc, p53 and apoptosis as indicators of different aggressiveness in small lymphocytic lymphoma (SLL) // Eur. J. Haematol. -1997. Vol. 59, N3.-P. 148−154.
- Pescarmona E., De-Sanctis V., Pistilli A. et. al. Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas // J. Pathol. -1997. Vol. 183, N3. -P. 281−286.
- Pesce A., Fuzibet J. -G. Systemic markers in Non-Hodgkin's lymphomas II New Techniques and Treatments. 4-th Cancer Res. Workshop, Grenoble 1984.(Karger, Basel 1985). -P. 56−60.
- Pezzella F., Gatter K. What is value of bcl-2 protein detection for histopathologists? II Histopathol. -1995. -Vol.26. -P.89−93.
- Prognostic Factors in Aggressive Non-Hodgkin's Lymphoma / Malignant Lymphomas: Biology and Treatment Ed. Pangalis G.A.-Springer-Verlag Berlin Heidelberg.-1995.-P.103−127.
- Pezzella F., Tse A., Cordell J. et al. Expression of the bcl-2 protein is not specific for the 14:18 chromosomal translocation // Am. J. Pathol. -1990. -Vol.137. -P.225−232.
- Pezzella F., Turley H., Kuzu I. et al. bcl-2 protein in non-small-cell lung carcinoma. Immunohistochemical evidence for abnormal expression and correlation with survival // New Engl. J. Med.-1993. -Vol.329. -P.690- 694.
- Pezzella F., Gatter K., Mason D. et al. BCL-2 protein expression in follicular lymphomas in absence of 14- 18 translocation // Lancet.-1990.-NI. P.1510.
- Piris M., Pezella F. et al. p53 and bcl-2 expression in high-grade B-cell lymphomas correlation with survival time // Br. J. Cancer. -1994. -Vol.69. P.337−341.
- Portlock C. Management of the low-grade non-Hodgkin's lymphoma // Semin. Oncol. -1990. -Vol.17. P.51- 59.
- Qi X., Simonson M., Distelhorst C.W. Bcl-2 inhibits c-fos induction by calcium // Oncogene. -1997. Vol. 15, N23. — P. 2849- 2853.
- Rack K., Salomon-Nguyen F., Radford-Weiss I. etal. FISH detection of chromosome 14q32/lgH translocations: evaluation in follicular lymphoma//Br. J. Haematology. -1998. -Vol.103, N2. -P.495−504.
- Reed J. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematological malignancies II Semin. Hematol. -1997. Vol. 34, N4 Suppl 5. — P. 9−19.
- Reed J. Bcl-2 family proteins: strategies for overcoming chemoresis-tance in cancer//Adv. Pharmacol. -1997. Vol. 41. — P. 501−532.
- Rezuke W., Abernathy E., Tsongalis G. Molecular diagnosis of B- and T-cell lymphomas: fundamental principles and clinical applications // Clin. Chem. -1997. Vol. 43, N10. — P. 1814−1823.
- Richardson M., Quanguang C., Filippa D. et al. Intermediate to high grade histology of lymphomas carrying t (14−18) is associated with additional nonrandom chromosome change // Blood.-1987.-Vol.70.-P.444- 447.
- Shipp M. Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has «high-risk disease?» // Blood. -1994. -Vol. 83, № 5 (March 1). -P. 1165−1173.
- Sklar J. Polymerase chain reaction: the molecular microscope of residual disease//J. Clin. Oncol. -1991. -Vol.9. -P.1521- 1524.
- Soini Y., Raunio H., Paakko P. High-grade malignant non-Hodgkin's lymphomas differ from low-grade lymphomas in the extent of apoptosis and their expression of bcl-2, mcl-1, bax and p53 // Tumor. Biol. -1998. Vol. 19, N3. — P. 176−85.
- Stamatopoulos K., Kosmas C., Belessi C. et al. Molecular insights into the immunopathogenesis of follicular lymphoma // Immunology today. -2000. -Vol.21, N6. -P.298−305.
- Takano Y., Saegusa M., Masuda M. et. al. Apoptosis, proliferative activity and Bcl-2 expression in Epstein-Barr-virus-positive non-Hodgkin's lymphomas II J. Cancer. Res. Clin. Oncol. -1997. Vol. 123, N7.-P. 395−401.
- The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive Non-Hodgkin's lymphoma. II N. Engl. J. Med. -1993. P.987−994.
- Tormo M., Tari A.M., McDonnell T.J. et. al. Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation // Leuk. Lymphoma. 1998. — Vol. 30, N3−4. — P. 367- 379.
- Trumper L., Brady G., Bagg A. et al. Single-cell analysis of Hodgkin and Reed-Sternberg cell: molecular heterogeneity of gene expression and p53 mutations // Blood. -1993. -Vol.81. -P.3097−115.
- Trumper L.H. Brady G. et al. Gene expression in single Reed-Sternberg cells of Hodgkin’s disease: Results from PCR generated single cell cDNA libraries //Ann. Oncol. -1992. -Vol.3, suppl 4.1. P.25- 26.
- Tsujimoto Y., Croce C. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma II Proc. Natl. Acad. Sci. USA. -1986. -Vol.83. -P.5214.
- Tsujimoto Y., Crossman E., Jaffe E. et al. Involvement of the bcl-2 gene in human follicular lymphoma II Science. -1985. -Vol.228. -p. 1440−1443.
- Tsujimoto Y., Finger L., Yunis J. et al. Cloning of the chromosome breakpoint of neoplastic В cells with the t (14−18) chromosome translocation // Science.-1984.-Vol.226.-P.1097−1099.
- Tsujimoto Y., Gorham I., Cossman J. et al. The t (14−18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining // Nature.-1985.-Vol.229.-P.1390−1393.
- Tsujimoto Y., Gorham J., Cossman J. et al. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma//Oncogen. -1987. -Vol.2. -P.3−7.
- Utz G., Swerdlow S. Distinction of follicular hyperplasia from follicular lymphoma in B5-fixed tissues: comparison of MT2 and bcl-2 antibodies // Human. Pathol. -1993. -Vol.24. -P.1155−1158.
- Van-Haselen C., Vermeer M., Toonstra J. et. al. p53 and bcl-2 expression do not correlate with prognosis in primary cutaneous large T-cell lymphomas II J. Cutan. Pathol. -1997. Vol. 24, N8. -P. 462−467.
- Vaux D., Cory S., Adams M. bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells II Nature. -1988. -Vol.335. -P.440- 442.
- Veis D., Sorensen C., Shutter J. et al. bcl-2 deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys and hypopigmented hair// Cell. -1993. -Vol.75. -P.229- 240.
- Vitolo U., Gaidano G., Botto B. et. al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients // Ann. Oncol. 1998. — Vol. 9, N1.1. P. 55−61.
- Volm M. Multidrug Resistance and its reversal II Anticancer Res-1998.-Vol.18. -P.2905- 2918.
- Walker A., Taylor S., Hickman J. et al. Germinal center-derived signals act with Bcl-2 to decrease apoptosis and increase clonogenicity of drug-treated human В lymphoma cells // Cancer. Res. -1997. Vol. 57, N10. — P. 1939−1945.
- Wang H., Reed J. Mechanisms of Bcl-2 protein function // Histol. Histopathol. -1998. Vol. 13, N2. — P. 521- 530.
- Weisenburger D., Gascoyne R., Bierman P. et al. Clinical significance of the t (14−18) and BCL2 overexpression in follicular large cell lymphoma // Leuk. Lymph. 2000. -Vol.36, N5−6.1. P.613- 523.
- Weiss N. Clinical epidemiology: the study of the outcomes of illness II New York. Oxford University Press. 1986.
- Wheaton S., Netser J., Guinee D. et. al. Bcl-2 and bax protein expression in indolent versus aggressive B-cell non-Hodgkin's lymphomas II Hum. Pathol. -1998. Vol. 29, N8. — P. 820- 825.
- Wilson W., Teruya-Feldstein J., Fest T. et. al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas II Blood. -1997. Vol. 89, N2. — P. 601−609.
- Wu G., El-Deiry W. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2 // Clin. Cancer. Res.-1996.-Vol.2,N4.-P.623- 633.
- Yunis J., Frizzera G. et al. Multiple recurrent genomic defects in follicular lymphoma // N. Engl. J. Med.-1987. -Vol.316. -P.79−84.
- Zhang A., Ohshima K., Sato K. et al. Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas//Pathol. Int. 1999.-Vol. 49, № 12.-P. 1043−52.
- Zhang X., Safah H., Mudad R. et. al. Frequency of BCL-2/J (H) translocations in peripheral blood of follicular lymphoma patients // Am. J. Hematol. -1997. Vol. 55, N4. — P. 205- 207.